November 19, 2026. Merck & Co., the U.S. drugmaker known internationally as MSD, announced a research collaboration with Isomorphic Labs to discover small-molecule candidates for an oncology target. The announcement does not identify the target or disclose payment amounts. Merck announcement
Who does what
Isomorphic will use its IsoDDE drug-design engine for computational predictions and molecular designs, incorporating selected proprietary Merck data. Merck will handle preclinical and clinical development, manufacturing and commercialization of any resulting products. Isomorphic Labs announcement
The agreement provides an upfront payment, potential research, development, regulatory and commercial milestone payments, and tiered royalties on net sales. Isomorphic also has an option to co-fund development for higher royalties. Future milestone payments depend on specified achievements. Terms disclosed by Merck
Why it matters
OX8 analysis. The business proposition combines an AI provider’s design capability with a drugmaker’s private research data and development infrastructure. That gives the AI company a route to commercial value through research payments and potential downstream royalties, rather than requiring it to carry every development activity itself.
The agreement establishes a commercial relationship. It does not establish that a candidate is safe, effective or approved, or that AI will reduce development costs or timelines. Those outcomes require evidence beyond the partnership announcement.
What to watch next
Watch for disclosure of the target, experimental validation of proposed molecules, development milestones and any move into human trials. Financial disclosures would also help investors assess the scale of the upfront commitment and contingent payments. Until then, the economics remain only partly visible and the scientific payoff remains uncertain.


Leave a Reply